The Daily Toke

March 27, 2026

# THC & Politics: The Battle Over Legalization, Revenue, and Federal Rules

Recreational and medical marijuana legalization continues reshaping American politics in March 2026, with activists, lawmakers, and economists all racing to define what legal cannabis looks like before federal restrictions tighten. Idaho's Natural Medicine Alliance announced it has exceeded the signature threshold to place a medical cannabis measure on November's ballot, commissioning an economic analysis projecting $108.5 million in annual retail sales by Year 6 under a Utah-comparable model. 💰 MONEY MOVES The state could collect between $12.8 million and $28 million annually in taxes and fees depending on the final regulatory structure—a pitch activists are framing as medical freedom rather than recreation, with messaging centered on patient dignity, job creation, and an alternative to opioid dependency.

Across the country, the political calculus around legalization is shifting. Tennessee Democrats filed the "Pot for Potholes Act," tying recreational legalization directly to infrastructure funding through a 15% state tax on cannabis sales, while Louisiana's House Bill 373 proposes a limited adult-use pilot program running 2027–2030 under its existing medical marijuana operators—a structure that has already drawn criticism for protecting a two-company duopoly rather than opening the market to genuine competition. Indiana Governor Mike Braun, a Republican, publicly warned his state will "probably have to address" marijuana legalization to avoid being the laggard among neighbors, a statement that signals growing bipartisan recognition that prohibition is increasingly untenable. Meanwhile, Massachusetts voters face a ballot question that would essentially repeal 2016's legalization, with opponents of the rollback pointing out the logical trap: allowing adults to possess and gift up to an ounce of cannabis while banning retail sales would likely create the black market conditions the rollback campaign claims to fear.

The Army's new recruitment policy, effective April 20, now allows recruits with a single marijuana possession conviction to enlist without needing a waiver—a practical acknowledgment that cannabis criminalization conflicts with military manpower needs. 🚀 THIS IS COOL Yet federal policy remains contradictory and chaotic. Congress has filed 16 cannabis-related bills in the 2025–2026 session, including the MORE Act (62 sponsors, the most of any current proposal) to fully deschedule cannabis, the STATES 2.0 Act to shield state-legal operators from federal prosecution, and a bipartisan Hemp Planting Predictability Act to delay new federal restrictions on hemp-derived THC products by three years. Representative James Comer (R-KY), chair of the House Oversight Committee, is urging Congress to delay new restrictions on intoxicating hemp products, warning that federal rules threaten a $28.4 billion market.

But the hemp and THC landscape is fractionalizing at the state level. Ohio's Senate Bill 56 took effect on March 21, introducing sweeping restrictions including limits on intoxicating hemp, bans on THC and CBD beverages, and criminal penalties for transporting cannabis outside a car's trunk or consuming it in public—reversing voter-approved legalization with legislative fine-tuning. Arizona's House Judiciary Committee advanced a bill to criminalize "excessive" cannabis smoke or odor with up to four months in jail. Delaware approved hospital use of medical cannabis for terminally ill patients. And Virginia's Cannabis Control Authority is streamlining business licensing while implementing strict testing and labeling rules, though critics argue the state's tax structure could push consumers back to the black market. 💰 MONEY MOVES The broader market is stabilizing: Whitney Economics projects U.S. legal marijuana sales will reach $30.5 billion in 2026 after 2025's first-ever annual decline in the history of the regulated market, with growth resuming at a more modest pace as supply saturation and pricing compression reshape the industry.

The political fracture is deepest at the federal level. While advocates push for full descheduling or safe harbor protections for state-legal businesses, House Judiciary Committee Ranking Member Jamie Raskin warned that a federal bill to expedite deportation of non-citizens could classify a group of high school students who regularly smoke cannabis—even in a legal state—as a "criminal gang," opening them to deportation. 🤔 THINK ABOUT IT The U.S. military now welcomes recruits with cannabis convictions, multiple states are moving toward legalization, an economic market worth $30 billion annually is under construction, yet Congress can simultaneously draft bills that would criminalize the same activity with deportation consequences. That contradiction is the current state of American cannabis policy: localized normalization colliding with federal legal machinery still built on 50-year-old prohibition architecture.

March 27, 2026

# Hemp Ban Watch: Texas, Ohio, and the National Crackdown

Texas is moving fast. Beginning March 31—just days away—the state's Department of State Health Services will ban smokable hemp products including pre-rolled joints and flower, implement a dramatic licensing fee increase from $155 to $5,000 annually for retailers, and adopt a new "Total THC" standard that counts THCA (a compound that converts to delta-9 when heated) toward the 0.3 percent threshold. The change effectively wipes out inventory overnight for thousands of retailers. Industry players estimate the Texas hemp market, worth approximately $8 billion, could face a major shakeout with widespread closures among roughly 1,500 hemp shops across the state. Edibles and beverages will remain legal, but for shops built around higher-margin smokable products, the financial pivot may not be enough to survive.

💰 MONEY MOVES The licensing fee increase alone—from $258 to $10,000 for manufacturers and $155 to $5,000 for retailers—represents a prohibitive barrier designed less as regulation and more as effective industry suppression. Boomtown Vapor LLC filed a lawsuit in Travis County on March 17 challenging both the Total THC standard and the new fees, arguing the state health department is overstepping its authority and that the regulations constitute a "prohibitive tax" rather than reasonable oversight. A temporary restraining order was requested to prevent immediate business closures and industry-wide layoffs, though a judge has not yet ruled. The legal challenge hinges on the 2019 House Bill 1325, which defined legal hemp solely by Delta-9 THC levels—not total THC—and argues the agency cannot unilaterally redefine that standard.

Ohio already crossed the finish line. On March 19, Ohio's Senate Bill 56 took effect, banning intoxicating hemp products, THC beverages, and CBD drinks entirely. The law passed after activists failed to gather enough signatures for a November ballot referendum to block it. Hemp farmer Joey Ellwood, based in Tuscarawas County, warned that 6,000 Ohio businesses will be affected, adding that customers who depend on these products for stress, sleep, pain, and anxiety now face pressure to turn to pharmaceuticals or cross state lines. Mark Fashian, president of hemp product wholesaler Midwest Analytical Solutions in Delaware, Ohio, announced he's leaving the state rather than risk felony charges—he previously worked with more than 500 stores across Ohio, all of which are now in panic mode pulling products off shelves. A lawsuit was filed in Franklin County Court seeking a temporary restraining order, but a judge rejected the emergency request, and the law stands.

Meanwhile, other states are charting their own courses. South Carolina's Senate just advanced sweeping regulations that would restrict hemp-THC drinks to liquor stores only, ban gummies except in licensed retail locations, and prohibit anyone under 21 from possessing these products—striking a middle ground between outright ban and free-market sales. Pennsylvania lawmakers in Berks County are calling for action, with State Senator Judy Schwank (D.) noting that materials being sold are "much stronger than they were before" and State Representative Manny Guzman (D.) describing the current landscape as "the wild west," where products marketed as "hemp" could contain K2, Delta-8, or undisclosed ingredients. Governor Josh Shapiro has proposed legalizing marijuana, which would require the state to establish legitimate testing and regulation—currently absent in the gray area between federal and state law.

🤔 THINK ABOUT IT The pattern is unmistakable: states are moving toward either outright bans or heavily restrictive regulations on hemp-derived THC products, often without clear evidence of harm. Meanwhile, alcohol—which kills approximately 95,000 Americans annually—remains widely available to adults. Prescription opioids kill over 16,000 Americans per year. Cannabis has zero recorded overdose deaths in human history. Yet in Texas, Ohio, and now South Carolina and Pennsylvania, politicians are treating a zero-death product with greater urgency than substances proven to cause tens of thousands of deaths annually. The timing matters too: these crackdowns follow the 2018 Farm Bill, which created the legal gray area that allowed the hemp market to explode. Now that the market exists—with real jobs, real revenue, and real customers who say these products help with sleep, pain, and anxiety—states are asking: do we regulate this or eliminate it entirely? The answer varies dramatically depending on which side of the state line you're on.

March 27, 2026

# THC in Science: Major Findings Challenge Mental Health Claims, While New Pain and Liver Research Show Promise

Researchers at the University of Sydney have delivered a sobering conclusion that contradicts years of patient hope: medical cannabis shows little to no strong evidence for treating anxiety, depression, or PTSD. The largest review of medical cannabis and mental health to date, published in The Lancet Psychiatry, found that cannabinoid-based treatments simply don't work for these conditions at the rates patients and advocates have claimed. This comes as multiple major studies reach similar conclusions—that cannabis is "rarely justified" for mental health disorders despite widespread self-medication and medical recommendations. The findings suggest that while cannabis may feel helpful in the moment, the science doesn't support its use as a reliable psychiatric intervention, which matters enormously for the millions of Americans considering it as an alternative to traditional antidepressants and anti-anxiety medications.

But the picture looks dramatically different for physical pain, particularly in older adults. 🚀 THIS IS COOL A new study published in the Journal of Pain Research found that CBD-dominant full-spectrum marijuana extracts outperformed synthetic THC (dronabinol) across every measured outcome in treating chronic pain. Researchers analyzed 968 patients aged 65 and older over 24 weeks using data from Germany's Pain e-Registry. The results were striking: 85.7% of patients on CBD-dominant extracts met the study's primary success benchmark—meaningful pain relief without stopping treatment due to side effects—compared to just 21.9% on synthetic THC. Adverse reactions occurred in 15.5% of CBD users versus 35.7% of THC users, and discontinuation rates were five times lower in the CBD group. For older adults managing arthritis, neuropathy, and other chronic pain conditions, the research suggests whole-plant CBD extracts may offer better relief with fewer complications than pharmaceutical alternatives. The researchers noted that findings are exploratory and need confirmation through randomized controlled trials, but the signal is clear.

At the cellular level, cannabis compounds are showing unexpected promise against diseases that currently have no cure. 🚀 THIS IS COOL Researchers at Hebrew University of Jerusalem discovered that cannabidiol (CBD) and cannabigerol (CBG) improved liver function in mouse models of non-alcoholic fatty liver disease, a condition affecting approximately 24% of American adults. The mechanism is novel: both compounds enhanced hepatic energy production and lysosomal function—essentially giving the liver a "backup battery" through increased creatine and phosphocreatine levels. A separate study found that cannabis compounds may help calm brain inflammation in Alzheimer's disease, targeting a pathway that protein-focused treatments have overlooked. While both studies remain in preclinical phases, they suggest cannabis compounds could address metabolic and neurodegenerative diseases that millions of Americans currently have no good options for treating. The gap between "works in mice" and "works in humans" is significant, but these findings open entirely new therapeutic territory.

Meanwhile, the federal government just created a major new legal framework that's already sparking controversy. 💰 MONEY MOVES The Centers for Medicare & Medicaid Services announced the first official details of a pilot program launching April 1st to provide insurance coverage for hemp-derived CBD and THC products, with beneficiaries eligible for up to $500 annually in covered cannabinoid products. The program allows up to 3 milligrams of THC per product—but that could change if President Trump's recently signed law to recriminalize hemp THC products takes effect without delay. The move has triggered fierce debate about whether CMS is circumventing FDA drug approval standards. Critics argue that covering unproven cannabis products as medicine without FDA approval sets a dangerous precedent and could undermine the pharmaceutical approval process. Supporters counter that access matters more than bureaucratic gatekeeping for patients already using these products. 💰 MONEY MOVES Industry analysts estimate CBD wellness and recreational products could reach $8.5 billion to $13 billion in sales in 2026 alone—making this regulatory clarity a major financial moment for the cannabis market.

But regulation itself is becoming the battle. A major federal provision set to ban most hemp-derived CBD products by November has sparked pushback from policy experts and cannabis researchers. Daniel Kruger, a cannabis policy researcher at the University at Buffalo, argues that an outright CBD ban is unnecessary if proper regulation is in place. "A better approach would be to regulate these products, mandate their testing, and have a certificate of analysis accessed through a QR code," Kruger said, noting that the ban was influenced by a white paper backed by delta-9 THC product makers highlighting contamination issues in unregulated products. The logic is straightforward: test everything, label everything clearly, and regulate similar substances similarly rather than banning one compound while legal alcohol and pharmaceuticals face far looser oversight. 🤔 THINK ABOUT IT The impulse to ban low-THC hemp products comes from concern about unregulated markets—but wouldn't regulated markets solve the actual problem without removing access for the millions of Americans currently using CBD for arthritis, anxiety, insomnia, and general wellness?

On the enforcement side, technology is catching up to policy. Cannabix Technologies and Omega Laboratories announced significant progress on a breath-based THC detection system designed to identify recent marijuana use within hours—a major gap in current drug testing. Unlike urine, hair, or oral fluid tests that detect cannabis weeks or months after use, breath-based detection could distinguish between past use and present impairment, addressing a critical need as cannabis legalization expands across North America. The challenge is that THC is fat-soluble and non-volatile, requiring novel lab analysis to detect picogram-level concentrations in exhaled breath. If the technology validates, it could transform workplace safety, law enforcement, and public health policy by finally answering the question: "Is someone actually impaired right now?" Meanwhile, Congress has filed 16 cannabis-related bills in the 2025-2026 session, including the MORE Act (62 sponsors), which would remove marijuana from the Controlled Substances Act entirely, and the Hemp Planting Predictability Act (36 sponsors), which would delay the November CBD ban for three years. The legislative momentum suggests normalization pressure is building, even as scientific questions about mental health claims remain unresolved.

March 27, 2026

# Texas Hemp Industry Faces March 31 Regulatory Cliff as New Rules Threaten $8 Billion Sector

Texas hemp retailers are scrambling as sweeping new state regulations take effect Tuesday, March 31, fundamentally reshaping a booming industry that has exploded since 2019. The Texas Department of State Health Services' new rules will impose a "Total THC" standard that counts THCA alongside Delta-9 THC to meet a 0.3% threshold—a shift that effectively bans smokable products like joints and flower buds that currently dominate retail sales across the state's estimated 1,500 hemp shops. Boomtown Vapor LLC filed a lawsuit in Travis County on March 17 seeking a temporary restraining order, arguing the regulatory shift would render nearly its entire inventory illegal overnight and claiming the state is overstepping its authority. A judge has yet to rule on the restraining order request, which business owners say is essential to prevent immediate closures and widespread layoffs.

💰 MONEY MOVES The financial hit extends far beyond lost product sales. Retail registration fees are jumping from $155 to $5,000 annually, while manufacturer licenses will skyrocket from $258 to $10,000 per facility—increases industry players warn will force closures and potentially push customers toward illicit markets. The hemp sector, estimated at $8 billion and providing jobs across roughly 1,500 retail locations occupying millions of square feet in Texas strip malls and shopping centers, faces what some analysts describe as an existential threat. The regulations also impose new child-resistant packaging requirements, testing standards, updated labeling, and raise the legal purchasing age to 21—changes that add compliance costs on top of the fee increases.

Edibles and beverages will remain legal under the new regime, potentially offering a lifeline for some retailers willing to pivot their business models. But shop managers in Denton and San Antonio report that customers—particularly military veterans—are expressing significant concern about losing access to smokable products they've relied on for sleep, relaxation, and pain management. Julio Martinez, manager of Smoke N Chill in Denton, noted that veterans have been panicking about the changes, asking questions shop staff cannot yet answer. Bee's Wellness Cafe owner Brook Richie expressed frustration that state officials are "basically telling them how they can get their medicine," while San Antonio's David Burrow, CEO of Alamo Botanicals, argued the state should have focused on tighter testing and compliance oversight rather than an outright functional ban.

The dispute highlights a fundamental tension: are these regulations designed to ensure product safety and compliance, or to eliminate a thriving industry that state officials have signaled disapproval of? Dispensary operators like Richie argue that targeted enforcement of existing testing requirements would address legitimate safety concerns without decimating legal businesses. 🤔 THINK ABOUT IT Texas banned smokable hemp products while alcohol—which kills approximately 95,000 Americans annually—remains fully legal and socially normalized. Cannabis has zero recorded overdose deaths in human history. So which regulatory approach actually prioritizes public health?